glp 1 analog drugs GLP-1 Receptor Agonists as Treatments for Type 2 Diabetes GLP1 Receptor Agonists—Effects beyond Obesity
Description
The updated model emphasizes that aging is not driven by a single mechanism, but emerges from a network of interacting biological systems that link molecular damage to systemic physiological decline
Motor performance and functionality improvements were seen, with a lower disability score observed in the intranasal insulin group compared to baseline scores, suggesting that intranasal insulin may be a feasible treatment for PD
[DOI] [PMC free article] [PubMed] [Google Scholar] 112.Moll H., Frey E., Gerber P., et al
Semin Pediatr Surg
A recombinant human glucagon-like peptide (GLP)-1-albumin protein (albugon) mimics peptidergic activation of GLP-1 receptor-dependent pathways coupled with satiety, gastrointestinal motility, and glucose homeostasis
Impact of GLP-1 and GLP-1 receptor agonists on cardiovascular risk factors in type 2 diabetes
